FrancophonIA/ELRC3.0 huggingface dataset:
English: 5% Dextrose Injection BP
Estonian: 5% glükoosi süstelahus
English: There was no evidence of accumulation of cefuroxime in the serum from normal volunteers following repeat intravenous administration of 1500 mg doses every 8 hours.
Estonian: Pärast 1500 mg annuste korduvat veenisisest manustamist iga 8 tunni järel ei täheldatud tsefuroksiimi kuhjumist tervete vabatahtlike seerumis.
English: 1 g powder for solution for injection or infusion Italy - Curoxim
Estonian: 1 g süste- või infusioonilahuse pulber Itaalia - Curoxim
English: Tell your doctor if this applies to you.
Estonian: Kui see kehtib teie kohta, rääkige sellest oma arstile.
English: Gram-negative anaerobes:
Estonian: Gramnegatiivsed anaeroobid:
English: 500 mg powder for solution for injection Italy - Curoxim
Estonian: 500 mg süstelahuse pulber Itaalia - Curoxim
English: Streptococcus mitis (viridans group)
Estonian: Streptococcus mitis (viridans grupp) Gramnegatiivsed aeroobid:
English: The average renal clearance ranges from 114 to 170 mL/min/1.73 m2 following IM or IV administration over the dosage range of 250 to 1000 mg.
Estonian: Pärast 250...1000 mg annuste lihase- või veenisisest manustamist on keskmine renaalne kliirens 114...170 ml/min/1,73 m2.
English: Contact a doctor or nurse immediately if you get any of these symptoms.
Estonian: Kui teil tekib mõni nendest sümptomitest, võtke otsekohe ühendust oma arsti või meditsiiniõega.
English: Gram-positive aerobes:
Estonian: Grampositiivsed aeroobid:
English: 2 g powder for solution for infusion Italy - Curoxim
Estonian: 2 g infusioonilahuse pulber Itaalia - Curoxim
English: Complicated urinary tract infections, including pyelonephritis Soft-tissue infections: cellulitis, erysipelas and wound infections
Estonian: Olmetekkene pneumoonia ja kroonilise bronhiidi ägenemine Pehmete kudede infektsioonid: tselluliit, erüsiipelas ja haavainfektsioonid Intraabdominaalsed infektsioonid
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients [To be completed nationally] 6.2 Incompatibilities [To be completed nationally] 6.3 Shelf life
Estonian: 6.1 Abiainete loetelu [Täidetakse riiklikult]
English: Amount per vial
Estonian: Viaali suurus
English: Zinacef 250 mg , 750 mg and 1.5 g powder for solution for injection; Zinacef 250 mg, 750 mg and 1.5 g powder for solution for injection or infusion IM/IV.
Estonian: Zinacef 250 mg, 750 mg ja 1,5 g süstelahuse pulber; Zinacef 250 mg, 750 mg ja 1,5 g süste- või infusioonilahuse pulber i.m./i.v.
English: • skin rash, which may blister, and looks like small targets (central dark spot surrounded by a paler area, with a dark ring around the edge) erythema multiformae.
Estonian: mida ümbritseb kahvatum ala, mida omakorda ümbritseb piki äärt tume ring) multiformne erüteem.
English: 750 mg, 1.5 g powder for solution for infusion (Monovial presentation).
Estonian: 750 mg, 1,5 g infusioonilahuse pulber (Monovial).
English: Dose mg
Estonian: Annus (mg)
English: • to prevent infections during surgery.
Estonian: Zinacef'i kasutatakse ka: • infektsioonide vältimiseks operatsiooni ajal.
English: INSTRUCTIONS ON USE [To be completed nationally]
Estonian: ABIAINED [Täidetakse riiklikult]
English: Soft-tissue infections: cellulitis, erysipelas and wound infections.
Estonian: Pehmete kudede infektsioonid: tselluliit, erüsiipelas ja haavainfektsioonid Intraabdominaalsed infektsioonid
English: Zinacef 750 mg, 1.5 g and 2 g powder for solution for infusion IV
Estonian: Zinacef 750 mg, 1,5 g ja 2 g infusioonilahuse pulber
English: Gram-negative aerobes: Acinetobacter spp.
Estonian: Acinetobacter spp.
English: Zinacef 250 mg, 500 mg, 750 mg and 1 g powder and solvent for solution for injection IM/IV
Estonian: Zinacef 250 mg, 500 mg, 750 mg ja 1 g süstelahuse pulber ja lahusti i.m./i.v.
English: 250 mg, 500 mg, 750 mg, 1 g powder and solvent for solution for injection Powder and solvent for solution for injection [To be completed nationally]
Estonian: 250 mg, 500 mg, 750 mg, 1 g süstelahuse pulber ja lahusti Süstelahuse pulber ja lahusti [Täidetakse riiklikult]
English: Zinacef 250 mg, 500 mg, 750 mg and 1 g powder and solvent for solution for injection Intramuscular or intravenous use.
Estonian: Zinacef 250 mg, 500 mg, 750 mg ja 1 g süstelahuse pulber ja lahusti Intramuskulaarne või intravenoosne.
English: 250 mg, 750 mg, 1.5 g powder for solution for injection or infusion Powder for solution for injection or infusion [To be completed nationally]
Estonian: 250 mg, 750 mg, 1,5 g süste- või infusioonilahuse pulber Süste- või infusioonilahuse pulber [Täidetakse riiklikult]
English: Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens can be achieved in the tonsilla, sinus tissues, bronchial mucosa, bone, pleural fluid, joint fluid, synovial fluid, interstitial fluid, bile, sputum and aqueous humour.
Estonian: Annuste 250...1000 mg lihase- või veenisisese manustamise järgselt on keskmine jaotusruumala 9,3...15,8 l/1,73 m2. Sagedaste haigustekitajate suhtes minimaalset inhibeerivat kontsentratsiooni ületav tsefuroksiimi kontsentratsioon saavutatakse kurgumandlites, ninakõrvalkoobaste kudedes, bronhide limaskestas, luudes, pleuravedelikus, liigesevedelikus, sünoviaalvedelikus, interstitsiaalvedelikus, sapis, rögas ja vesivedelikus.
English: (intravenously) given as 2 or 3 divided doses (see section 5.2)
Estonian: 30...100 mg/kg ööpäevas (intravenoosselt), manustatuna 2 või 3 väiksemaks annuseks jagatuna (vt lõik 5.2)
English: Shake the vial to reconstitute the cefuroxime sodium.
Estonian: Loksutage viaali tsefuroksiimnaatriumi lahustamiseks.
English: 250 mg powder for solution for injection
Estonian: 250 mg süstelahuse pulber
English: Gram-positive anaerobes:
Estonian: Grampositiivsed anaeroobid:
English: Zinacef 750 mg and 1.5 g powder for solution for infusion (Monovial presentation) Intravenous use.
Estonian: Zinacef 750 mg ja 1,5 g infusioonilahuse pulber (Monovial) Intravenoosne.
English: 250 mg, 750 mg, 1.5 g powder for solution for injection Powder for solution for injection [To be completed nationally]
Estonian: 250 mg, 750 mg, 1,5 g süstelahuse pulber Süstelahuse pulber [Täidetakse riiklikult]
English: 750 mg, 1.5 g powder for solution for infusion (Monovial presentation) Powder for solution for infusion [To be completed nationally]
Estonian: 750 mg, 1,5 g infusioonilahuse pulber (Monovial) Infusioonilahuse pulber [Täidetakse riiklikult]
English: Zinacef 750 mg, 1.5 g and 2 g powder for solution for infusion Intravenous use.
Estonian: Zinacef 750 mg, 1,5 g ja 2 g infusioonilahuse pulber i.v.
English: Zinacef 750 mg and 1.5 g powder for solution for infusion (Monovial presentation)
Estonian: Zinacef 750 mg ja 1,5 g infusioonilahuse pulber (Monovial)
English: 750 mg, 1.5 g, 2 g powder for solution for infusion Powder for solution for infusion [To be completed nationally]
Estonian: 750 mg, 1,5 g, 2 g infusioonilahuse pulber Infusioonilahuse pulber [Täidetakse riiklikult]
English: Patients on haemodialysis
Estonian: Naatriumisisaldus viaalis
English: • Community acquired pneumonia.
Estonian: • Olmetekkene pneumoonia.
English: Zinacef 750 mg and 1.5 g powder for solution for infusion (Monovial presentation) IV
Estonian: Zinacef 750 mg ja 1,5 g infusioonilahuse pulber (Monovial) i.v.
English: "click" is heard.
Estonian: „klõpsatus“.
English: Compound Sodium Lactate Injection BP (Hartmann's Solution).
Estonian: M/6 naatriumlaktaadi süstelahus naatriumlaktaat-liitsüstelahus (Hartmanni lahus)
English: • a widespread rash with blisters and peeling skin.
Estonian: • nahalööve, sügelev mügarlik lööve (nõgestõbi)
English: Renal impairment
Estonian: Ringeri süstelahus
English: No data are available for women under 18 years.
Estonian: Alla 18-aastaste naiste kohta puuduvad andmed.
English: The dose of 200 mg should not be exceeded.
Estonian: Annust 200 mg ei tohi ületada.
English: The Mifepristone Linepharma tablet should be swallowed with some water in the presence of a doctor or a member of his/her medical staff.
Estonian: Mifepristone Linepharma tablett tuleb koos veega alla neelata arsti või tema meditsiinilise meeskonna liikme juuresolekul.
English: Medical termination of developing intra-uterine pregnancy up to 63 days of amenorrhea.
Estonian: Areneva emakasisese raseduse meditsiiniline katkestamine kuni amenorröa 63. päevani.
English: Summary of product characteristics and package leaflet
Estonian: Ravimi omaduste kokkuvõte ja pakendi infoleht
English: The method of administration is 200 mg of mifepristone (1 tablet) should be taken, followed 36 to 48 hours later by the administration of a prostaglandin analogue ( 1 pessary containing 1 mg of gemeprost placed in the vagina).
Estonian: Manustamisviis on järgmine: esmalt tuleb võtta 200 mg mifepristooni (1 tablett), millele järgneb 36 kuni 48 tundi hiljem prostaglandiini analoogi manustamine (tuppe sisestatav pessaar, mis sisaldab 1 mg gemeprosti).
English: HOW TO USE MIFEPRISTONE LINEPHARMA Always take Mifepristone Linepharma exactly as your doctor has told you.
Estonian: Võtke Mifepristone Linepharma't alati täpselt nii, nagu arst on teile selgitanud.
English: The method of administration is 200 mg of mifepristone in a single oral dose, followed 36 to 48 hours later by the administration of the prostaglandin analogue gemeprost 1 mg per vaginam.
Estonian: Manustamisviis on järgmine: 200 mg mifepristooni ühekordse suukaudse annusena, millele järgneb 36 kuni 48 tundi hiljem 1 mg prostaglandiini analoogi gemeprosti manustamine tupesiseselt.
English: Mifepristone Linepharma is for oral use.
Estonian: Mifepristone Linepharma on mõeldud suukaudseks kasutamiseks.
English: The valid package leaflet is the final version achieved during the Coordination group procedure with the following amendments (highlighted below in bold underlined) in section 3:
Estonian: Kehtiv pakendi infoleht on viimane versioon, mis valmis kooskõlastusrühma menetluse käigus ja sisaldab järgmisi parandusi (allpool paksus ja allajoonitud kirjas esile tõstetud) lõigus 3.
English: Amendments to be included in the relevant sections of the package leaflet
Estonian: Pakendi infolehe asjakohastesse lõikudesse lisatavad parandused
English: Amendments to be included in the relevant sections of the summary of product characteristic
Estonian: Ravimi omaduste kokkuvõtte asjakohastesse lõikudesse lisatavad parandused
English: The valid summary of product characteristics is the final version achieved during the Coordination group procedure with the following amendments (highlighted below in bold underlined) in the section
Estonian: Kehtiv ravimi omaduste kokkuvõte on viimane versioon, mis valmis kooskõlastusrühma menetluse käigus ja sisaldab järgmisi parandusi (allpool paksus ja allajoonitud kirjas esile tõstetud) lõigus 4.2.
English: The company will also provide long-term post-marketing safety data.
Estonian: Ettevõte esitab ka pikaajalised turustamisjärgsed ohutusandmed.
English: It is available as capsules (20 mg).
Estonian: Seda turustatakse kapslitena (20 mg).
English: The recommended dose is one capsule once a day.
Estonian: Soovitatav annus on üks kapsel üks kord ööpäevas.
English: The medicine presented no major safety concerns and the risks were considered to be manageable.
Estonian: Ravim ei tekitanud suuri ohutusprobleeme ja riske peeti vastuvõetavateks.
English: The main measure of effectiveness was based on an assessment of the patients' nerve damage and quality of life after 18 months of treatment.
Estonian: Efektiivsuse põhinäitaja tugines patsiendi närvikahjustuse hinnangule ja elukvaliteedi hinnangule pärast 18-kuulist ravi.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Vyndaqel on 16 November 2011.
Estonian: Euroopa Komisjon andis Vyndaqeli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. novembril 2011.
English: What measures are being taken to ensure the safe and effective use of Vyndaqel?
Estonian: Mis meetmed võetakse, et tagada Vyndaqeli ohutu ja efektiivne kasutamine?
English: The results did not include patients with more severe disease who left the study early because they needed to undergo a liver transplant.
Estonian: Tulemused ei hõlma raskema haigusega patsiente, kes lahkusid uuringust, sest nad vajasid maksasiirdamist.
English: This means that because transthyretin amyloidosis is rare, for scientific reasons, it has not been possible to obtain complete information about Vyndaqel.
Estonian: See tähendab, et harvaesineva haiguse tõttu teaduslikel põhjustel ei olnud Vyndaqeli kohta võimalik saada täielikku teavet.
English: The CHMP therefore concluded that the benefits of Vyndaqel are greater than its risks and recommended that it be granted marketing authorisation.
Estonian: Seetõttu otsustas inimravimite komitee, et Vyndaqeli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Vyndaqel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Vyndaqeli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The material will include a leaflet containing information on the risks of the medicine including the risks to the unborn baby and on how to contribute to a post-marketing study and a surveillance programme for pregnant women.
Estonian: Teabematerjal sisaldab ravimi riskide teabelehte (kus on ka teave ravimi riskist lootele), samuti teavet, kuidas osaleda rasedate patsientide turustamisjärgses uuringus ja järelevalveprogrammis.
English: The full EPAR for Vyndaqel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Vyndaqeli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: For more information about treatment with Vyndaqel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Vyndaqeliga toimuva ravi kohta lisateavet, lugege pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Vyndaqel.
Estonian: See on ravimi Vyndaqel Euroopa avaliku hindamisaruande kokkuvõte.
English: It attaches to transthyretin, which prevents the protein from breaking up, thereby stopping the formation of amyloid and slowing down the progression of the nerve disease.
Estonian: See kinnitub transtüretiinile ja takistab selle lagunemist, mis peatab amüloidi tekke ning aeglustab närvihaiguse progresseerumist.
English: The active substance in Vyndaqel, tafamidis, is a transthyretin stabilizer.
Estonian: Vyndaqeli toimeaine tafamidis on transtüretiini stabilisaator.
English: The company that makes Vyndaqel will carry out a study on the effects of the medicine in a subgroup of patients with certain genetic mutations.
Estonian: Vyndaqeli tootja teeb uuringu ravimi mõju kohta teatud geenimutatsioonidega patsientide alamrühmas.
English: The most common side effects with Vyndaqel (seen in more than 1 patient in 10) are urinary tract infection (infection of the structures that carry urine), vaginal infection, upper abdominal pain (stomach ache) and diarrhoea.
Estonian: Vyndaqeli kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on kuseteede infektsioon, tupeinfektsioon, ülakõhu valu ja kõhulahtisus.
English: Other information about Vyndaqel
Estonian: Muu teave Vyndaqeli kohta
English: Vyndaqel is a medicine that contains the active substance tafamidis.
Estonian: Vyndaqel on ravim, mis sisaldab toimeainena tafamidist.
English: Vyndaqel was compared with placebo (a dummy treatment) in 128 patients with transthyretin amyloidosis.
Estonian: Vyndaqeli võrreldi platseeboga (näiv ravim) 128 patsiendil, kellel oli transtüretiiniga seotud amüloidoos.
English: Vyndaqel is used in adult patients with the early stage of nerve disease (stage 1).
Estonian: Vyndaqeli kasutatakse täiskasvanud patsientidel närvihaiguse varajases I staadiumis.
English: The company that markets Vyndaqel will provide educational material to all doctors expected to prescribe Vyndaqel.
Estonian: Vyndaqeli turustav ettevõte annab teabematerjalid kõikidele ravimit määravatele arstidele.
English: In patients with transthyretin amyloidosis, a blood protein called transthyretin is defective and breaks easily.
Estonian: Transtüretiiniga seotud amüloidoosiga patsientidel on verevalk transtüretiin defektne ja laguneb kergesti.
English: In 45% of patients taking Vyndaqel, nerve function either improved or stabilised, compared with 30% of patients taking placebo.
Estonian: Närvifunktsioonid paranesid või stabiliseerusid Vyndaqeli võtnud patsientidest 45%-l ja platseebot võtnutest 30%-l.
English: For the full list of all side effects and restrictions with Vyndaqel, see the package leaflet.
Estonian: Vyndaqeli kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vyndaqel.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The CHMP noted that, apart from in patients who left the study because they needed a liver transplant, Vyndaqel was more effective than placebo in delaying nerve damage in patients with transthyretin amyloidosis.
Estonian: Inimravimite komitee märkis, et muudel patsientidel kui need, kes lahkusid uuringust maksasiirdamise vajaduse tõttu, toimis Vyndaqel efektiivsemalt kui platseebo, aeglustades transtüretiiniga seotud amüloidoosiga patsientidel närvikahjustuste teket.
English: What information is still awaited for Vyndaqel?
Estonian: Mis teavet Vyndaqeli kohta veel oodatakse?
English: What is the risk associated with Vyndaqel?
Estonian: Mis riskid Vyndaqeliga kaasnevad?
English: Because the number of patients with transthyretin amyloidosis is low, the disease is considered ‘rare', and Vyndaqel was designated an ‘orphan medicine' (a medicine used in rare diseases) on 28 August
Estonian: Et transtüretiiniga seotud amüloidoosiga patsientide arv on väike ja see haigus esineb harva, nimetati Vyndaqel 28. augustil 2006 harvikravimiks.
English: What is Vyndaqel?
Estonian: Mis on Vyndaqel?
English: Vyndaqel is used to delay nerve damage caused by transthyretin amyloidosis, a hereditary disease in which fibres called amyloid build up in tissues around the body including around the nerves.
Estonian: Vyndaqeli kasutatakse transtüretiiniga seotud amüloidoosi (pärilik haigus, mille korral kogu organismis, samuti närvikiudude ümber tekivad amüloidsed fibrillid) põhjustatud närvikahjustuste progresseerumise aeglustamiseks.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vyndaqel have also been included in the summary of product characteristics and the package leaflet.
Estonian: Vyndaqeli omaduste kokkuvõttesse ja pakendi infolehele lisati ravimi ohutu ja tõhusa kasutamise teave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Why has Vyndaqel been approved?
Estonian: Miks Vyndaqel heaks kiideti?
English: The broken protein forms a fibrous substance called amyloid that is deposited in tissues and organs around the body, including around nerves, where it interferes with their normal functions.
Estonian: Lagunenud valgust tekib kiulise struktuuriga aine amüloid, mis koguneb organitesse ja kudedesse, samuti närvide ümber, takistades nende normaalset toimimist.
English: Vyndaqel has been authorised under ‘exceptional circumstances'.
Estonian: Vyndaqeli müügiluba anti erandkorras.
English: How does Vyndaqel work?
Estonian: Kuidas Vyndaqel toimib?
English: How has Vyndaqel been studied?
Estonian: Kuidas Vyndaqeli uuriti?
English: What benefit has Vyndaqel shown during the studies?
Estonian: Milles seisneb uuringute põhjal Vyndaqeli kasulikkus?
English: How is Vyndaqel used?
Estonian: Kuidas Vyndaqeli kasutatakse?
English: What is Vyndaqel used for?
Estonian: Milleks Vyndaqeli kasutatakse?
English: Treatment should be started and supervised by a doctor knowledgeable in the management of patients with this disease.
Estonian: Ravi Vyndaqeliga tohib alustada üksnes kõnealuse haiguse ravis kogenud arst ning ravi peab toimuma tema järelevalve all.
English: Vyndaqel was more effective than placebo at treating patients with transthyretin amyloidosis.
Estonian: Transtüretiiniga seotud amüloidoosiga patsientide ravis oli Vyndaqel efektiivsem kui platseebo.
English: EU/1/09/537/001 Mozobil
Estonian: EU/1/09/537/001
English: Subcutaneous use vial (glass)
Estonian: Subkutaanne Viaal (klaas)
English: MA (EU) number (Invented) name Strength Pharmaceutical Form
Estonian: Müügiloa nr Euroopa Liidus (Väljamõeldud) nimetus
English: 20 mg/ml Solution for injection
Estonian: 20 mg/ml Süstelahus
English: _*_One 2-ml dose contains: rotavirus serotype* G1
Estonian: _*_ Üks 2 ml annus sisaldab: rotaviiruse serotüüpi* G1
English: 2 As lower confidence limit (p = 0.95)
Estonian: 1 Nakkuslikud ühikud 2 Alumise usalduspiirina (p=0,95)
English: not less than 2.3 x 106 IU1, 2 * human-bovine rotavirus reassortants (live), produced in Vero cells.
Estonian: mitte vähem kui 2,0x106 IU1, 2 rotaviiruse serotüüpi* P1[8] mitte vähem kui 2,3x106 IU1, 2
English: ( 93 days)
Estonian: ( 93 päeva)
English: The method of administration is as follows:
Estonian: Manustamismeetod on järgmine:
English: 3 - 6 years old
Estonian: 3 - 6 aastat
English: 11 months
Estonian: 11 kuud
English: One implant.
Estonian: Üks implantaat.
English: Fish should be anaesthetised.
Estonian: Kalad peavad olema anesteseeritud.
English: Do not use Gonazon before approximately 10% of the specific broodstock population has ovulated naturally.
Estonian: Mitte kasutada Gonazoni enne, kui ligikaudu 10% sugukarja populatsioonist on looduslikult ovuleerunud.
English: Not for use in fish from which eggs
Estonian: Mitte kasutamiseks kaladel, kelle
English: Benzyl alcohol (1%)
Estonian: Bensüülalkohol (1%)
English: Gonazon for dogs: Intervet GesmbH Siemensstrasse 107 A-1210 Wien Austria
Estonian: Gonazon koertele: Intervet GesmbH Siemensstrasse 107 A-1210 Wien Austria
English: Intraperitoneal (IP) use
Estonian: Intraperitoneaalne(IP) manustamine
English: Gonazon for fish:
Estonian: Gonazon kaladele:
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/.
Estonian: Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti (EMEA) koduleheküljelt aadressil http://www.emea.europa.eu/.
English: In some cases this can be related to the use of the compound too early in the spawning season.
Estonian: Mõnedel juhtudel võib see olla seotud preparaadi liiga varajase manustamisega kudemisperioodil.
English: Simultaneous administration of five implants during a oneyear period was well tolerated.
Estonian: Viie implantaadi üheaegne manustamine 1 aastase perioodi kestel oli hästi talutav.
English: GnRH analogues are peptides.
Estonian: GnRH analoogid on peptiidid.
English: Separate empty sterile containers
Estonian: Eraldi tühi steriilne konteiner
English: No antidotes are available.
Estonian: Antidoot puudub.
English: ATC vet code: QH01CA
Estonian: ATC-vet kood: QH01CA
English: Therefore, drug interactions would not be expected to occur.
Estonian: Seetõttu ei peaks ravimi koostoimeid tekkima.
English: An overdose will not accelerate the onset or increase the degree of ovulation.
Estonian: Üledoos ei kiirenda ovulatsiooni algust ega suurenda ovulatsiooni.
English: Fig.4
Estonian: Joon.4
English: Preferred injection volume per kg fish (depending on fish
Estonian: Soovituslik süstelahuse kogus kg kala kohta (sõltuvalt